Washington Trust’s Exact Sciences EXAS Stock Holding History

Washington Trust’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30	Closed	-$3K	–	1015
2020 Q3	$3K	Hold	30	–	–	﹤0.01%	838
2020 Q2	$3K	Buy	+30	New	+$2.4K	﹤0.01%	742

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Washington Trust's EXAS Position: Q4 2020 in Review

Washington Trust sold out of Exact Sciences (EXAS) in Q4 2020, closing a stake of 30 shares — an estimated $3K sold.

Washington Trust first reported a position in EXAS in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 622 funds tracked by Wall St. Rank hold EXAS as of Q4 2020.

Washington Trust reported no remaining Exact Sciences position as of Q4 2020 after selling out during the quarter.
Washington Trust sold 30 Exact Sciences shares in Q4 2020, an estimated $3K.
Washington Trust first reported a position in Exact Sciences in Q2 2020 and held it in 2 quarters.
Washington Trust's Exact Sciences position peaked at $3K in Q3 2020.
622 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2020.

Based on Washington Trust's 13F filing for Q4 2020, filed 9 Feb 2021.